China SXT Pharmaceuticals, Inc.
$2.06
▲
5%
2026-04-21 09:42:00
www.sxtchina.com
NCM: SXTC
Explore China SXT Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.97 M
Current Price
$2.06
52W High / Low
$1,046.98 / $1.25
Stock P/E
—
Book Value
$26.16
Dividend Yield
—
ROCE
-17.13%
ROE
-50.3%
Face Value
—
EPS
$-57.15
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
75
Beta
1.75
Debt / Equity
5.95
Current Ratio
4.37
Quick Ratio
3.4
Forward P/E
—
Price / Sales
1.29
Enterprise Value
$-18.31 M
EV / EBITDA
2.2
EV / Revenue
-11.9
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | InterCure Ltd. | $0.75 | — | $125.93 M | — | -8.41% | -16.68% | $605 / $225.3 | $7.59 |
| 2. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
| 3. | Apimeds Pharmaceuticals US, Inc. | $1.88 | — | $23.64 M | — | 126.09% | 209.61% | $40.31 / $1.61 | $0.65 |
| 4. | BioCryst Pharmaceuticals, Inc. | $9.19 | 8.7 | $2.3 B | — | 107.2% | -88.68% | $11.31 / $6 | $-0.56 |
| 5. | Amneal Pharmaceuticals, Inc. | $13.26 | 58.7 | $4.23 B | — | 14.23% | -80.04% | $15.42 / $7.01 | $-0.23 |
| 6. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
| 7. | Collegium Pharmaceutical, Inc. | $34.31 | 17.33 | $1.09 B | — | 14.67% | 23.7% | $50.79 / $25.86 | $9.51 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.74 M | 1.93 M | 1.97 M | 2.6 M |
| Operating Profit | -2.68 M | -2.52 M | -5.61 M | -5.19 M |
| Net Profit | -3.3 M | -3.1 M | -5.93 M | -5.74 M |
| EPS in Rs | -3.87 | -3.63 | -6.95 | -6.72 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 21.66 M | 23.13 M | 29.55 M | 33.55 M |
| Total Liabilities | 6.22 M | 9.2 M | 14.86 M | 17.12 M |
| Equity | 15.44 M | 13.93 M | 14.69 M | 16.42 M |
| Current Assets | 21.3 M | 14.23 M | 19.52 M | 22.45 M |
| Current Liabilities | 6.01 M | 8.9 M | 14.5 M | 17.12 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -2.35 M | -1.93 M | -0.08 M | 0.27 M |
| Investing CF | 0.06 M | 0.03 M | -0.01 M | -0.05 M |
| Financing CF | 8.4 M | -2.62 M | 2.94 M | 1.6 M |
| Free CF | -2.35 M | -1.94 M | -0.15 M | 0.21 M |
| Capex | -0 M | -0.01 M | -0.07 M | -0.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -9.73% | -2.19% | -24.23% | — |
| Earnings Growth % | -6.62% | 47.79% | -3.46% | — |
| Profit Margin % | -189.77% | -160.67% | -301% | -220.43% |
| Operating Margin % | -153.97% | -130.42% | -284.4% | -199.43% |
| Gross Margin % | 21.11% | 28.73% | 21.62% | 48.1% |
| EBITDA Margin % | -147.8% | -121.91% | -264.13% | -194.11% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-02-03 | 1:0.00666667 |
| 2023-10-05 | 1:0.04 |